In a new study, researchers found that treatment with Bimagrumab is safe and effective for treating excess adiposity and metabolic disturbances of adult patients with obesity and type 2 diabetes.
Bimagrumab is an antibody that blocks activin type II receptors and stimulates skeletal muscle growth.
The research was conducted by …
In the study, the team tested 75 patients with type 2 diabetes, body mass index between 28 and 40 and glycated hemoglobin A1c levels between 6.5% and 10%.
Patients were injected with either Bimagrumab or a placebo every 4 weeks for 48 weeks.
Both groups received diet and exercise counseling. The research took place at nine sites in the United States and the United Kingdom from February 2017 to May 2019.
At the end of the 48-week study, the team found a nearly 21% decrease in body fat in the Bimagrumab group compared to 0.5% in the placebo group.
The results also revealed the Bimagrumab group gained 3.6% of lean mass compared with a loss of 0.8% in the placebo group.
The combined loss in total body fat and gain in lean mass led to a net 6.5% reduction in body weight in patients receiving Bimagrumab compared with 0.8% weight loss in their counterparts receiving the placebo.
These results suggest that there may be a novel way to achieve weight loss with a profound loss of body fat and an increase in lean mass, along with other metabolic benefits.
One author of the study is Steve Heymsfield, MD, FTOS, past president of The Obesity Society.
The study was presented in a research forum titled “Emerging Pharmacological Anti-obesity Therapies” at ObesityWeek.
Copyright © 2021 Knowridge Science Report. All rights reserved.
